HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin in combination with chemotherapy.

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: f633cefcbec5384d39b001e72b5b32925a5f9582
First added on: Jan 16, 2026